

Psychosocial Predictors of Medication Adherence among Persons Living with HIV

Aurélie Gauchet, Cyril Tarquinio, and Gustave Fischer

5 *Background:* Since the introduction of highly active antiretroviral therapy (HAART), many have learned to live with HIV as a chronic illness. Adherence to medical regimens is extremely important for HIV patients. *Purpose:* To examine the extent to which medication adherence among HIV patients is related to social and psychological variables. *Method:* Data were gathered among 127 HIV patients (aged from 10 18–65 years) recruited at their quarterly consultation at Metz Hospital (France). Subjects completed a self-report adherence to medication scale, the Illness Perception Questionnaire (IPQ), the Beliefs about Medicine Questionnaire (BMQ), a French Value System Scale, a treatment satisfaction scale, and sociodemographic measures. *Results:* Analyses revealed significant associations between adherence and patients' 15 beliefs about treatment, satisfaction with treatment, confidence in the physician, some values ("other people," "god and children"), and duration of treatment and illness. *Conclusion:* The data suggest that patients' beliefs about treatment are formed to a certain degree in the patients' relationship with the physician. Furthermore, adherence seems to be related to personal values.

20 *Key words:* medication adherence, HIV infection, values, believes, self regulatory model

The efficacy of highly active antiretroviral therapy (HAART) offers the possibility of dramatic clinical improvement and prolonged life for persons infected with the human immunodeficiency virus-, or HIV (Karon, Fleming, Stekete, & De Cock, 2001; Murphy et al., 2001). Of the many factors that influence treatment success (e.g., disease stage, antiretroviral treatment history, and presence of resistant strains of HIV), adherence to antiretroviral medications seems crucial in determining the success or failure of antiretroviral therapy (Chesney et al., 2000b; Perno et al., 2002; Van Vaerenbergh et al., 2002). Even occasional nonadherence to HAART may result in virologic failure and the emergence of drug-resistant strains. In one study that documented the high levels of adherence needed for effective HAART, Paterson et al. (2000) reported that virologic failure occurred in 72% of individuals with less than 95% adherence but in only 22% of individuals with 95% or greater adherence.

Although it is widely recognized that adherence to HAART is vital to treatment success, adherence is often poor (Bangsberg et al., 2000; Lucas, Chaisson, & Moore, 1999; Liu et al., 2001; Nieuwkerk et al., 2001; Paterson et al., 2000). There are many potential reasons for poor adherence. The HAART regimen can be complex, often involving three or more medications, up to eight daily pills, and dietary restrictions. Many individuals experience immediate and long-term side effects including fatigue, nausea, diarrhea, insomnia, abnormal fat accumulation, taste alterations, and peripheral neuropathy (Ammassari et al., 2001; Chesney et al., 2000a). All these factors, combined with the long-term nature of the course of treatment, may result in poor adherence among seropositive individuals.

While there is growing consensus that multicomponent intervention approaches are more effective in enhancing adherence (Haynes, 2002; Roter et al., 1998; Wright, 2000), the mechanisms by which the interventions enhance adherence need clarification.

That situation led Reynolds (2003) to propose a model for antiretroviral (ARV) medication adherence, using Leventhal's self-regulation theory (Diefenbach & Leventhal, 1996; Leventhal et al., 1997) and supporting theoretical and empirical work (e.g., Alonzo & Reynolds, 1995; Reynolds & Alonzo, 2000). Leventhal's theory brings a patient-centered understanding to the dynamic factors involved in adherence.

Aurélie Gauchet, Department of Psychology, University of Miami, Coral Gables, FL; Cyril Tarquinio and Gustave Fischer, University of Metz, France.

The authors thank Charles S. Carver for comments on earlier versions of the manuscript and S. T. Calvin for statistical suggestions.

Correspondence concerning this article should be addressed to Aurélie Gauchet, Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., Coral Gables, FL 33124-0751. E-mail: GauchetA@aol.com

65 This theory suggest that people seek to understand their
illness by developing a working model or representa-
tion of what the illness is, its causes, its effects, how
long it will last, and whether it can be cured or con-
70 trolled. Representations are elaborated through the per-
son's idiosyncratic symptom and illness episodes and
information obtained through social and cultural chan-
nels. These representations do not necessarily conform
to scientific views, but they have been found to guide
health behaviors (Reynolds, 2003).

75 In this view, people are thought to be motivated to
minimize their health-related risks and act to reduce
health threats in ways consistent with their perceptions
of them. This model suggests that adherence to ARV
medications will be influenced by whether adherence
80 makes sense to the patient, given his or her particu-
lar illness representation. It can be readily seen that
several factors that have been identified as particularly
important to ARV adherence (e.g., illness experiences,
interactions with others, cognitive function) may in-
volve the individual's HIV illness representation.

85 Illness representations are not the only represen-
tations that people form. They may also form represen-
tations of treatments. It has been suggested that
decisions about taking medication are likely to be in-
formed by beliefs about the medicines as well as beliefs
90 about the illness they are intended to treat or prevent
(Horne, 1997). This principle is recognized in a recent
report from the Royal Pharmaceutical Society of Great
Britain, which has identified the role of medication
beliefs in treatment adherence as a priority for future
95 research (Marinker, 1997; Royal Pharmaceutical Soci-
ety of Great Britain, 1997). Moreover, necessity beliefs
and concerns have been shown to relate to adherence
in a range of chronic illness (Horne et al., 2004).

100 The patient-provider relationship has been identi-
fied as another important factor influencing adherence
to treatment (Roberts, 2002). Aspects of the patient-
provider relationship including trust, consistency, and
continued interaction have been identified as being
105 particularly important (Baken et al., 2000; Ickovics
& Meisler, 1997; Singh et al., 1996). Further, patient
adherence to medications has been enhanced when
providers give clear explanations and provide full dis-
closure of potential adverse events, and when they offer
encouragement, reassurance, and support (Davis et al.,
110 1997). This pathway is the main subject of the study
reported here. In this study, we want to test whether
confidence in physician predicts medication adherence
directly, and may also predict it indirectly, through pa-
tients' beliefs about treatment.

115 Another class of variable that appears relevant to
the problem of adherence is values. Many authors
have demonstrated the link between values and be-
haviors (Rokeach, 1973; Schwartz, 1992; Fischer &
Tarquinio, 2002). Indeed, values are often considered
120 as representing the underpinnings of behavior. In this

view, people create a system of personal values from
their experiences with their physical and social envi-
ronment, their culture, and so on, and they then pro-
ceed to act from this system of values. To put it dif-
125 ferently, people decide what is important for them and
act accordingly. For instance, we wanted to show how
values like "spirituality" influence medication adher-
ence. Although the effect of spirituality on medica-
tion adherence per se is undocumented, persons di-
agnosed with life-threatening illness such as cancer 130
and HIV/AIDS have reported high levels of spiritual-
ity (Connor, Wicker, & Germino, 1990; Jenkins, 1995;
Zinnbauer et al., 1997), which have been highly corre-
lated with psychological adaptation and good health
outcomes (Kaczorowski, 1989; Simoni, Kerwin, & 135
Martone, 2002).

Other recent authors focused on models of adher-
ence with HAART. The most important factors seem
to be social support and positive provider interactions
(Simoni et al., 2006; Johnson et al., 2006b; Ironson 140
et al., 2005) and also adherence information (regi-
men, side effects, beliefs about treatment; Starace et
al., 2006; Johnson et al., 2006a).

In the present study, we examined how values, con-
fidence in one's physician, and patients' beliefs about 145
their treatment relate to medication adherence. We
chose these factors from the self-regulatory model of
antiretroviral adherence (Reynolds, 2003). We used
structural equation modelling in a diverse sample of 150
HIV-positive men and women to test whether confi-
dence in one's physician was an important factor for
patients' beliefs about treatment and for their medi-
cation adherence. Moreover, we wanted to analyse
the contribution of some values (importance of others,
155 spirituality) to medication adherence.

Method

Data for these analyses came from a cross-sectional
study that investigated the relations of psychosocial
variables to medication adherence among HIV-positive
160 men and women. Data were collected during 2001.

Participants

HIV-positive adult men and women between the
ages of 18 and 65 years who were currently prescribed
HAART were eligible for inclusion in this study. No
165 patient refused to participate in this study. Participants
were recruited from the Regional Hospital Centre in
Metz (France) during their quarterly consultation. Ini-
tially, 175 patients responded to recruitment efforts
and were screened for the study. After a preliminary
170 introduction to the study, 48 did not meet eligibility
criteria. Patients were included if they had been pre-
scribed some medicines for regular use in the treatment
of their illness for at least two months prior to the study,

PSYCHOSOCIAL PREDICTORS OF MEDICATION ADHERENCE AMONG PERSONS LIVING WITH HIV

175 if they are at least 18 years, if they are not psychotic
or demented, and if they could read and understand
the questionnaire and felt well enough to complete it.
The most common reasons for exclusion included partic-
180 ipation in other clinical research trials, no current
prescription for antiretroviral medication, inability to
read or write French, or evidence of significant cog-
nitive impairment. Data from 99 men and 28 women
were used in the analyses. The characteristics of the
main sample are shown in Table 1 and are described in
more detail below.

185 The majority of the sample was White (84.3%),
with 12.6% being Black/African. Thus, the sample
is representative of people living with HIV/AIDS in
France, with African women slightly underrepresented
and White men and women slightly overrepresented
190 (Organisation Mondiale de la Santé, 2002). A slight
majority (59.1%) had a high school diploma or less
education. The sample was fairly evenly divided be-
tween individuals who described their sexual orien-
tation as exclusively heterosexual (56%) and all the
195 others (44%). The average age of the sample was 40
years (SD = 9.20) and the mean time since HIV di-
agnosis was 96 months (SD = 53). Participants were
prescribed an average of 8 (SD = 3.9) daily antiretro-
viral pills.

200 **Procedure**

Informed consent was obtained from all participants
prior to participation. Qualified participants completed
a battery of psychosocial instruments via face-to-face
structured interviews and self-report formats. Each pa-
205 tient was met individually in a hospital office. The in-
vestigator stressed that the study was being conducted
by the University and was completely independent of
the hospital, and that responses were anonymous and
would not be seen by any of the staff involved in their
210 care. It was hoped that this would decrease social desir-
ability bias in responses (Abraham & Hampson, 1996).

Measures

215 *Medication Adherence.* A self-report adherence to
medication scale was devised for this study. This
scale was inspired by the medication adherence scale
of Tarquinio, Fischer, and Grégoire (2000). Non-
adherence was indicated by the tendency to forget to
take medication and to deliberately adjust or alter the
220 dose from that recommended by the physician. This
scale comprises 16 adherence statements. Three items
(e.g., “I sometimes forget to take my medicines” and
“I sometimes alter the dose of my medication”) are
scored on a 6-point Likert scale with reverse scoring
(where 1 = always and 6 = never). The remaining thir-
225 teen items (e.g., “I take the medicines prescribed by the
physician” and “I respect the whole recommendations
of my physician”) are phrased as direct statements per-

Table 1. Sociodemographic and Medical Features of the Sample

Variable	N = 127	% of Sample
Age (years)	M = 39.7	SD = 9.2
Gender		
Male	99	78
Female	28	22
Ethnicity		
White	107	84.3
Black/African	16	12.6
Other	4	3.1
Relationship		
status Single	60	47.2
Married	20	15.7
Divorced	14	11
Homosexual partnered	19	15
Heterosexual partnered	9	7.1
Widowed	5	3.9
Education		
< High school	27	21.3
High school	48	37.8
Some College	24	18.9
College graduate	28	22
HIV diagnosis		
1981–1990	29	23
1991–1996	48	38.1
1997–2002	49	38.9
HIV mode of transmission		
Homosexual intercourse	55	44
Heterosexual intercourse	30	24
Shared needles	15	12
Blood transfusion	4	3.2
Work accident	2	1.6
Unknown	19	15.2
Initiation of first HAART regimen		
<1996	24	20.7
1997–1999	51	44
2000–2002	41	35.3
Drug class		
Monotherapy	1	0.8
Bithery	8	6.7
Tritherapy	102	85.7
Quadritherapy	8	6.7
CD4 cell counts (cellules/mm ³)		
>500	33	43.4
200–500	27	35.5
<200	16	21.1
Viral load		
Detectable	65	51.6
Undetectable	61	48.4
Medication side effects		
Yes	93	73.2
No	34	26.8

230 taining to the frequency of adjusting medication doses
(scored on a 6-point scale where 1 = never and 6 = al-
ways). A total medication adherence score is obtained
235 by summing responses to each of the sixteen items.
Scores ranged from 16 to 96, with higher scores indi-
cating greater reported adherence.

Values. A scale of reported values was also devised
for this study. This scale derives from the work of
235 Rokeach (1973) and Schwartz (1992). HIV patients

were asked to indicate the importance of each value to them, before and after their disease. Items are scored with a 9-point Likert scale (where 0 = not at all important and 9 = very important). Principal component analysis on these items (using the non-orthogonal method of rotation, as recommended by Kline, 1994, and Cattell, 1995) yielded four categories of values, explaining 47% of the variance: “other people” (11 items: respect, tolerance, being understanding with others), “success” (11 items: have a good job, be competitive, richness), “God and children” (5 items: found a family, see the children grow up, believe in god), and “sexuality” (5 items: continue to have sex, the pleasure, love). We have chosen to use these categories of values (used in other studies about AIDS and cancer, Fischer & Tarquinio, 2002) to see their relations to medication adherence.

Beliefs about Medicines Questionnaire (BMQ). The BMQ (Horne et al., 1999) assesses commonly held beliefs about medicines. The BMQ is an 18-item scale used to assess beliefs about the medications one has been prescribed (10 items) and the use of medication in general (8 items). There are four subscales: Specific-Necessity (e.g., “Without my HAART I would be very ill”), Specific-Concerns (e.g., “I sometimes worry about the long-term effects of my HAART”), General-Overuse (e.g., “Doctors use too many medicines”), and General-Harm (e.g., “All medicines are poisons”). Responses to each statement were scored on a 5-point Likert scale (where 1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, and 5 = strongly agree).

Confidence in Physician. Participants were asked to indicate the level of their confidence in their physician (“how much are you confident in your physician”). The item was scored on a 5-point Likert scale (where 1 = strongly not confident and 5 = strongly confident). Most patients reported being very confident in their physician.

Statistical Analyses

First we calculated descriptive statistics, including means, standard deviations, ranges, and alpha reliabilities of all psychosocial and medication adherence. Next, to identify potentially confounding variables that would need to be controlled in later analyses, we used bivariate analyses (i.e., Pearson correlations, *t*-tests, and chi-squares) to examine the association of each measure of adherence with sociodemographic factor (i.e., sex, ethnicity, age, education, sexual orientation, and relationship status) and medical-related variables (i.e., time since HIV diagnosis, time since initiation of first HAART regimen, drug class, number of medication in regimen, and viral load), as well as side effects.

Finally, structural equation modelling (SEM) was used to evaluate the proposed model. SEM examines the structural relationships between values, confidence in the physician, and patients’ beliefs about treatment, and medication adherence.

SEM analysis was evaluated with the maximum-likelihood estimation and performed with STATISTICA software (version 6.1, Sepath model). Consistent with current recommendations, several goodness-of-fit indices were used in addition to the chi-square statistic that is sensitive to both the assumption of normality and sample size. Specifically, the overall model fit was assessed by examining the root-mean-square error of approximation (RMSEA) index, with values around .05 (the lower bound of the 90% CI under .05) indicating adequate fit (Bollen & Long, 1993; Browne & Cudeck, 1993); the standardized root-mean-square residual (SRMR) index, with values less than .09 as a criterion (Hu & Bentler, 1999); and the comparative fit index (CFI; Bentler, 1990), which indicates an adequate fit with values around .90 or greater (Newcomb, 1990, 1994).

Results

Descriptive Data

Means, standard deviations, ranges, and alpha reliabilities of all psychosocial measures are presented in Table 2. The table also includes means, standard deviations and alpha reliabilities for the level of adherence as assessed by the medication adherence scale.

Bivariate Analyses

In bivariate analyses, none of the adherence variables were related to any sociodemographic or medical-related variable or to side effects (see Table 3). Therefore, none of these variables were controlled in SEM. The only variables significantly related to

Table 2. Descriptive Statistics for Study Variables among 127 HIV-Positive Individuals

Factor and Indicators	Range	M	SD	Alpha Reliability
Values	0–9	7.68	1.08	.80
Other people	0–9	5.50	1.69	.78
Success	0–9	4.83	2.34	.69
God and children	0–9	7.53	1.53	.75
Sexuality	0–25	21.79	5.31	.72
BMQ				
Specific-Necessity	0–25	16.06	4.47	.68
Specific-Concerns	0–20	10.92	3.28	.64
General-Overuse	0–20	9.77	3.06	.70
General-Harm	0–5	4.59	0.63	—
Confidence with physician Adherence	0–96	81.37	9.61	.83

Note. BMQ = Beliefs about Medicine Questionnaire.

PSYCHOSOCIAL PREDICTORS OF MEDICATION ADHERENCE AMONG PERSONS LIVING WITH HIV

Table 3. *Determinants of Medication Adherence*

Variables	Modalities	Medication Adherence Score				
		N ¹	m	σ	t	p
Age	<39 yrs	60	5.02	0.7	-1.18	NS
	>39 yrs	62	5.15	0.4		
Educational experience	<College	72	5.06	0.6	-0.50	NS
	>College	50	5.11	0.5		
Gender	Male	95	5.03	0.60	-2.02	NS
	Female	27	5.29	0.5		
Relationship status	Single	57	5.10	0.5	-0.53	NS
	Partnered or married	20	5.17	0.4		
HIV mode of transmission	Sexual intercourse	82	5.45	0.7	-0.25	NS
	Blood transfusion	38	5.50	0.6		
Sexual orientation	Homosexual	53	5.40	0.6	-1.68	NS
	Heterosexual	29	5.53	0.7		
Drug class	Mono./Bitherapy	9	4.73	0.5	-2.04	NS
	Tri./Quadritherapy	110	5.13	0.6		
Side effect	Yes	89	5.04	0.6	-1.37	NS
	No	33	5.21	0.5		
Viral load	Detectable	63	5.37	0.7	-1.73	NS
	Undetectable	58	5.55	0.6		
Confidence in physician	Confident	41	5.24	0.7	-2.9	.004
	Very confident	81	5.58	0.6		
Confidence in therapy	Not at all/Not confident	29	5.08	0.8	-3.9	.000
	Confident/Very confident	93	5.58	0.5		
Confidence in medicine	Not at all/Not confident	34	5.14	0.8	-2.4	.018
	Confident/Very confident	88	5.59	0.5		
Beliefs in benefit of therapy	Yes	63	5.63	0.5	3.9	.000
	No	59	5.28	0.7		
Improvement of QoL with treatment	Yes	78	5.57	0.5	3.4	.001
	No	44	5.26	0.7		

¹The variations observed in the size of the sample are due to missing data (subjects did not want to or could not answer to some questions).

adherence were confidence in physician and confidence with therapy.

We also developed a multivariate model on medication adherence (see Table 4). The variables significantly contributing to medication adherence were du-

ration of treatment, duration of HIV infection (in years) and confidence in physician.

Model Testing with SEM

We wanted to test the associations of values, confidence in physician, patients’ beliefs about treatment, and medication adherence. We restricted our model to include only variables that correlated with medication adherence (see Table 5). We included three classes of values (“other people,” “success,” and “God and children”); confidence in one’s physician; two of patients’ beliefs about treatment (specific-concern and general-harm); and the score for total medication adherence as the end-point of the predictive path.

We tested whether confidence in physician would relate directly to medication adherence, and would relate indirectly, through patients’ beliefs about treatment. We also tested the influence of values on medication adherence. Accordingly, we tested a model with three “categories” of predictors of medication adherence: values, confidence in physician, and patients’ beliefs about treatment. This model also specified

Table 4. *A Multivariate Model on Medication Adherence among 127 HIV-Positive Individuals*

Variables	Medication Adherence		
	B	t	p
Constant	74.39	1.09	.28
Initiation of first HAART regimen (in years)	-0.06	-0.59	.55
Duration of treatment	-0.25	-2.10	.04
Time since HIV diagnosis (in years)	0.29	2.47	.01
Number of prescribed medicines	-0.09	-0.80	.42
CD4 cells count	-0.10	-0.94	.34
Confidence in physician	0.30	2.40	.02
Quality of life	0.21	1.69	.09

Note: Model Characteristics R multiple = .60; R² adjusted = .36; F(7,58) = 4,74, p = .000.

Table 5. Intercorrelations among Variables in the Study

	BMQ Specific Necessity	BMQ Specific Concern	BMQ General Harm	BMQ General Overuse	Physician's Confidence	Values Other People	Values Sexuality	Values God and Children	Values Success
BMQ specific concern	-,06								
BMQ general harm	-,22*	,39**							
BMQ general overuse	-,18*	,25**	,54**						
Physician's confidence	,27**	-,15	-,26**	-,33**					
Values Other people	,17*	-,04	-,04	-,10	,17*				
Values Sexuality	-,00	,13	,13	,11	,02	,27**			
Values God and children	,11	,19*	,10	,04	,09	,45**	,18*		
Values Success	-,10	-,07	-,02	-,03	,24**	,31**	,41**	,06	
Adherence	,31**	-,04	-,25**	-,21*	,31**	,27**	,01	,17*	,20*

* $p < 0.05$; ** $p < 0.01$.

physician's confidence as influencing patients' beliefs about treatment.

The overall model has an adequate fit to the data, $X^2(120, N = 127) = 23.16, p = .001, CFI = .96, RMSEA = 0.05$ (95% confidence interval = 0.03–0.06), SRMR = 0.07, and all factor loading and specified paths were significant (see Figure 1). In this model, the effect of physician's confidence on adherence is specified to be mediated in part by patients' beliefs about treatment. Greater confidence in the physician had a direct path to adherence. Confidence also had a positive path to stronger beliefs about the necessity of the antiretroviral treatment, which related to greater ad-

herence, and a negative path to the belief that medicines are generally harmful, which related to lower adherence. There were also direct paths from two classes of values ("others" and "God and children") to greater medication adherence.

This, of course, is not the only model that one might specify. It might be argued, for example, that beliefs about medicine influence confidence in the physician, rather than vice versa. To determine how well such an alternative model would account for the relationships among the variables, we also tested a model in which the order of paths for confidence in physician and beliefs about treatment was reversed. This model has a




Figure 1. Structural equation model of psychosocial influences on medication adherence among persons living with HIV. All paths are significant ($p < .05$). Model fit statistics were as follows : $X^2(120, N = 127) = 23.16, p = .001$, comparative fit index = .96, root-mean-square error of approximation = 0.05 (95% confidence interval = 0.03–0.06), standardized root-mean-square residual = 0.07.

fit that was less optimal: $X^2(124, N = 127) = 14.84$,
 $p = .001$, CFI = .95, RMSEA = 0.09 (95% confi-
380 dence interval = 0.07–0.1), SRMR = 0.08. The first
model (shown in Figure 1) therefore was retained as the
model that best accounted for the pattern of observed
relationships among variables.

Discussion

385 The present study examines relationships among
values, confidence in physician, patients' beliefs about
treatment, and medication adherence in a diverse sam-
ple of men and women living with HIV. As hypoth-
esized, greater confidence in one's physician was re-
390 lated to greater adherence. Moreover, we found that
values and patients' beliefs about treatment also re-
lated to adherence. The effect of confidence in the
physician was in part mediated by patients' beliefs
about treatment. These results are consistent with the
395 self-regulatory model for ARV adherence (Reynolds,
2003). This model suggests that the association be-
tween the patient-provider relationship and medication
adherence is mediated by HIV illness/medication rep-
resentation. In other words, the relationship between
400 confidence in physician and adherence is in part posi-
tively mediated by patients' beliefs about the necessity
of antiretroviral treatment and negatively mediated by
patients' beliefs about the harmfulness of medication
in general. The data are consistent with the position
405 that patients' beliefs about treatment are formed in
part from the patients' relation with the physician (the
information that he or she gives about antiretroviral
treatment, the side effects, the importance of taking
medication regularly). This suggests that the patient-
410 provider relationship is particularly important.

The present study improves on previous research
by including all of the theorized variables in a compre-
hensive model and testing this against an alternative
415 model. Does the relationship between confidence in
physician and beliefs about treatment also work in the
opposite direction? Although our data did not support
this direction of effects clearly, it is possible for the
relationship to be bidirectional. Individuals may have
some personal beliefs about their treatment and, for that
420 reason, become more or less confident in the physician.
Longitudinal modelling of confidence in physician and
patients' beliefs about treatment will be necessary to
fully understand how this process unfolds over time.

Our results also lend support to the direct link
425 between certain personal values and medication ad-
herence. Valuing tolerance, respectfulness, and under-
standing toward others predicted greater adherence.
Valuing family and beliefs in god also predicted greater
adherence. These values ("other people" and "god
430 and children") may be associated with social support,
which is well known to be related to adherence (Pa-

terson et al., 2000; Simoni et al., 2006; Weaver et al.,
2005). On the other hand, valuing "success" and "sex-
uality" did not relate to adherence. These findings sug-
435 gest that it may be useful to emphasize the relevance
of certain values as a way of improving medication
adherence.

In addition to theory building, our findings have
implications for intervention development and clinical
440 practice. They suggest that the social support (mea-
sured by valuing other people) received from an af-
firming other, an information-enhancing relationship,
an empathic listener (measured by the confidence with
physician), or a spiritual relationship is associated with
445 improved medication adherence. Consequently, adher-
ence may be increased through future efforts to im-
prove individuals' access to social support, whether by
encouraging them when safe and appropriate to con-
fide in a partner or close friends or by facilitating their
450 relationships with their medical care providers or with
peers who are on similar medication regimens (Cohen
et al., 2000; Uchino, 2004).

For spiritually inclined individuals, intervention fo-
cused on spiritual coping that could help to main-
455 tain a positive attitude and motivation toward health
should be explored further. Such interventions could
fill a culturally significant need for support (Jenkins &
Pargament, 1995). Although we could not examine the
effect of knowledge in our model (but we measured
460 beliefs about treatment), prior research has suggested
that it is at least a necessary, if not sufficient, factor in
adherence and should be addressed. Information about
specific medications, adherence strategies, the impor-
tance of adherence, and the management of side effects
465 needs to be communicated throughout the course of
treatment and not just at initiation. Medication adher-
ence training may also enhance the effects of HAART
(Antoni et al., 2006).

Interventions for HIV-positive persons on HAART
are especially needed (Simoni et al., 2003). Given
470 the lingering stigma surrounding HIV/AIDS, social
support may be especially important for persons on
HAART.

The current study has several limitations that should
475 be noted. First, the stability of results from structural
equation models depends in part on having a large sam-
ple size. This study would have benefited from a larger
sample. Moreover, as previously noted, longitudinal
modelling of the relationships between confidence in
480 the physician and patients' beliefs about treatment is
highly desirable to confirm the proposed relationships.
In addition, because we recruited patients during their
quarterly consultation and required our participants to
be healthy enough to attend a number of assessment
485 appointments, our results may not generalize to those
individuals with serious co morbid medical conditions
such as cancer or hepatitis, or advanced AIDS. Another
limitation is the use of a single unvalidated item to

PSYCHOSOCIAL PREDICTORS OF MEDICATION ADHERENCE AMONG PERSONS LIVING WITH HIV

- Horne, R., & Weinman, J. (1999). Patient's beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *Journal of Psychosomatic Research*, *47*, 555–567.
- 620 Horne, R., & Weinman, J. (2002). Self-regulation and self-management in asthma: Exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. *Psychology and Health*, *17*, 17–32.
- 625 Horne, R., Weinman, J., & Hankins, M. (1999). The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology and Health*, *14*, 1–24.
- Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indices in covariance structure analysis: Conventional criteria versus new alternatives. *Structural Equation Modelling*, *6*, 1–55.
- 630 Ickovics, J. R., & Meisler, A. W. (1997). Adherence in AIDS clinical trials: A framework for clinical research and clinical care. *Journal of Clinical Epidemiology*, *50*, 385–391.
- 635 Ironson, G., O'Cleirigh, C., Fletcher, M. A., Laurenceau, J. P., Balbin, E., Klimas, N., Schneidermann, N., & Solomon, G. (2005). Psychosocial factors predicts CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. *Psychosomatic Medicine*, *67*, 1013–1021.
- 640 Jenkins, R. A. (1995). Religion and HIV: Implications for research and intervention. *Journal of Social Issues*, *51*, 131–144.
- Jenkins, R. A., & Pargament, K. I. (1995). Religion and spirituality as resources for coping with cancer. In M. R. Somerfield (Ed.), *Psychosocial resource variables in cancer studies: Conceptual and measurement issues* (pp. 51–74). Binghamton, NY: Haworth Press.
- 645 Johnson, M. O., Elliott, T. R., Neilands, T. B., Morin, S. F., & Chesney, M. A. (2006a). A social problem-solving model of adherence to HIV medications. *Health Psychology*, *25*, 355–363.
- 650 Johnson, M. O., Chesney, M. A., Goldstein, R. B., Remien, R. H., Catz, S., Gore-Felton, C., Charlebois, E., & Morin, S. (2006b). Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A medication model. *AIDS Patient Care*, *20*, 258–268.
- 655 Kaczorowski, J. M. (1989). Spiritual well-being and anxiety in adults diagnosed with cancer. *Hospice Journal*, *5*, 105–115.
- Karon, J. M., Fleming, P. L., Steketee, R. W., & De Cock, K. M. (2001). HIV in the United States at the turn of the century. *American Journal of Public Health*, *91*, 1060–1068.
- 660 Kline, P. (1994). *An Easy Guide to Factor Analysis*. London/New York: Routledge.
- Leventhal, H., Meyer, D., & Nerenz, D. (1980). The common sense representation of illness danger. In S. Rachman (Ed.), *Contributions to Medical Psychology*. Oxford: Pergamon Press.
- 665 Leventhal, H., Zimmerman, R., & Gutmann, M. (1984). *Compliance: A self-regulation perspective*. In W. D. Gentry (Ed.), *Handbook of Behavioral Medicine*. New York: Guilford.
- Q8 Lenenthal, H., & Cameron, L. (1987). Behavioural theories and the problem of compliance. *Patient Education and Counselling*, *10*, 117–138.
- 670 Leventhal, H., Diefenbach, M., & Leventhal, E. A. (1992). Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. *Cognitive Therapy and Research*, *16*, 143–163.
- 675 Leventhal, H., Benyamini, Y., Brownlee, S., Diefenbach, M., Leventhal, E. A., Patrick-Miller, L., & Robitaille, C. (1997). Illness representations: Theoretical foundations. In K. J. Petrie & J. A. Weinman (Eds.), *Perceptions of health and illness: Current research and applications* (pp. 19–45). Singapore: Harwood Academic.
- 680 Liu, H., Golin, C. E., Miller, L., Hays, R., Beck, K., Sanandaji, S., Christian, J., Maldonado, T., Duran, D., Kaplan, A. H., & Wenger, N. (2001). A comparison of multiple measures of adherence to HIV protease inhibitors. *Annals of Internal Medicine*, *134*, 968–977. 685
- Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. *Annals of Internal Medicine*, *131*, 81–87. 690
- Marinker, M. (1997). From compliance to concordance: Achieving shared goals in medicine taking. *British Medical Journal*, *314*, 747–748.
- Morin, M., & Moatti, J-P. (1996). Observance et essais thérapeutiques: Obstacles psychosociaux dans la recherche sur le traitement de l'infection à VIH. *Natures, Sciences, Sociétés*, *3*, 2–15. 695
- Morin, M., Munzenberger, N., Souville, M., Moatti, J-P., & Gastaut, J. A. (1996). *Biases in recruitment and non-compliance in AIDS clinical trials*. XIth International Conference on AIDS, Vancouver, Canada. 700
- Murphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. F., Flanigan, T. P., Kumar, P. N., Mintz, L., Wallach, F. R., & Nemo, G. J. (2001). Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. *Annals of Internal Medicine*, *135*, 17–26. 705
- Newcomb, M. D. (1990). What structural modelling techniques can tell us about social support. In I. G. Sarason, B. R. Sarason, & G. R. Pierce (Eds.), *Social support: An interactional view* (pp. 26–63). New York: Wiley. 710
- Newcomb, M. D. (1994). Drug use and intimate relationships among women and men: Separating specific from general effects in prospective data using structural equation models. *Journal of Consulting and Clinical Psychology*, *62*, 463–476. 715
- Nieuwkerk, P. T., Gisolf, E. H., Reijers, M. H., Lange, J. M., Danner, S. A., & Spranger, M. A. (2001). Long term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. *AIDS*, *15*, 1985–1991.
- Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., & Squier, C. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Annals of Internal Medicine*, *133*, 21–30. 720
- Perno, C. F., Ceccherini-Silberstein, F., De Luca, A., Cozzi-Lepri, A., Gori, C., & Cingolani, A. (2002). Virologic correlates adherence to antiretroviral medications and therapeutic failure. *Journal of Acquired Immune Deficiency Syndromes*, *31*, S118–S122. 725
- Reynolds, N. R., & Alonzo, A. A. (1998). HIV informal care: Emergent conflict and growth. *Research in Nursing and Health*, *21*, 251–260. 730
- Reynolds, N. R., & Alonzo, A. A. (2000). Self-regulation: The commonsense Model of Illness Representation. In V. H. Rice (Ed.), *Handbook of stress and coping* (pp. 483–495). Thousand Oaks: Sage.
- Reynolds, N. R. (2003). The problem of antiretroviral adherence: A self-regulatory model for intervention. *Aids Care*, *15*, 117–124. 735
- Reynolds, N. R., Testa, M. A., Marc, L. G., Chesney, M. A., & Neidig, J. (2004). Factors influencing medication adherence beliefs and self-efficacy in persons naïve to antiretroviral therapy: A multicenter, cross-sectional study. *Aids Behavior*, *8*, 141–150. 740
- Roberts, K. J. (2002). Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. *AIDS Patient Care and STDs*, *16*, 43–50. 745
- Rokeach, M. (1973). *The nature of human values*. New York: Free Press.
- Royal Pharmaceutical Society of Great Britain. (1997). *From compliance to concordance: Achieving shared goals in medicine taking*. London. 750

GAUCHET, TARQUINIO, FISCHER

- Schwartz, S. H. (1992). Universals in the content and the structure of values: Theoretical advances and empirical tests in 20 countries. In M. P. Zanna (Ed.), *Advances in experimental social psychology* (vol. 25, pp. 1–65). New York: Academic Press. 755
- Simoni, J. M., Frick, P. A., Lockhart, D., & Liebovitz, D. (2002). Mediators of social support and antiretroviral adherence among an indigent population in New York. *AIDS Patient Care and STDs*, 16, 431–439. 760
- Simoni, J. M., Frick, P. A., Pantalone, D. W., & Turner, B. J. (2003). Antiretroviral adherence intervention: A review of current literature and ongoing studies. *Topics in HIV Medicine*, 11, 185–198. 765
- Simoni, J. M., Kerwin, J. F., & Martone, M. M. (2002). Spirituality and psychological adaptation among women with HIV/AIDS: Implications for counseling. *Journal of Counseling in Psychology*, 49, 139–147. 770
- Simoni, J. M., Frick, P. A., & Huang, B. (2006). A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. *Health Psychology*, 25, 74–81. 775
- Singh, N., Squier, C., Sivek, C., Wagener, M., Nguyen, M. H., & Yu, V. L. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. *AIDS Care*, 8, 261–269. 780
- Starace, F., Massa, A., & Amico, K. R. (2006). Adherence to antiretroviral therapy: An empirical test of the information-motivation-behavioral skills model. *Health Psychology*, 25, 153–162.
- Tarquino, C., Fischer, G.-N., Gauchet, A., Dodeler, V., Grégoire, A., & Romary, B. (2003). Compliance et concept de soi chez des patients atteints par le VIH: Une approche dynamique du soi. *Revue Internationale de Psychologie Sociale*, 16, 21–54.
- Tarquino, C., Fischer, G.-N., & Barracho, C. (2002). Le patient face aux traitements: Compliance et relation médecin-patient. In Fischer, G.-N. (Ed.), *Traité de Psychologie de la Santé*. Paris: Dunod. 785
- Tarquino, C., & Fischer, G.-N. (2001). Therapeutic compliance methodologies in HIV infection treatment: A comparative study. *Swiss Journal of Psychology*, 60, 136–160. 790
- Tarquino, C., Fischer, G.-N., & Grégoire, A. (2000). La compliance chez des patients atteints par le VIH: Validation d'une échelle française et mesure de variables psychosociales. *Revue Internationale de Psychologie Sociale*, 13, 61–91. 795
- Tucker, L. R., & Lewis, C. (1973). A reliability coefficient for maximum likelihood factor analysis. *Psychometrika*, 35, 417–437.
- Uchino, B. N. (2004). *Social support and physical health: Understanding the health consequences of relationships*. New Haven, CT: Yale University Press. 800
- Van Vaerenbergh, K., De Geest, S., Derdelinckx, I., Bobbaers, H., Carbonez, A., Deschamps, A., et al. (2002). A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. *Antiviral Chemistry and Chemotherapy*, 13, 231–240. 805
- Weaver, K. E., Liabre, M. M., Duran, R. E., Antoni, M. H., Ironson, G., Penedo, F. J., & Schneiderman, N. (2005). A stress and coping model of medication adherence and viral load in HIV-positive men and women on highly active antiretroviral therapy (HAART). *Health Psychology*, 24, 385–392. 810
- Weinman, J., Petrie, K., Moss-Morris, R., & Horne, R. (1996). The illness perception questionnaire: A new method for assessing the cognitive representation of illness. *Psychology and Health*, 11, 431–445.
- Zinnbauer, B. J., Pargament, K. I., Cole, B., Rye, M. S., Belavich, T. G., & Hipp, K. M. et al. (1997). Religion and spirituality: Un-fuzzifying the fuzzy. *Journal for the Scientific Study of Religion*, 36, 549–564. 815